GENETICALY DETERMINED ELEVATION OF THROMBOGENIC POTENTIAL OF BLOOD IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS

Abstract

THE AIM of the investigation was to study the occurrence and clinic-pathogenetic value of prothrombotic genotypes which are of the greatest clinical and prognosic value among hematogenic thrombophilias. PATIENTS AND METHODS. Examination was performed in 180 patients with chronic glomerulonephritis (mean age 22.3±0.8 years). In addition to complete clinical and instrumental examination used at the specialized nephrological clinic, with the help of polymerase chain reaction the diagnosis of a single nucleotide change of C677T in the gene of methylenetetrahydrofolate reductase, punctated gene mutation of V factor of blood coagulation, and G20210A mutation in 3’ nontranslated area of gene of II factor of blood coagulation (samples of genomic DNA was obtained from peripheral blood leukocytes by the method of phenol-chloroform extraction). The control group included 100 healthy subjects with similar demographic characteristics. RESULTS. It was found thst protrombogenic mutations under study can be found in patients with chronic glomerulonephritis more often than among healthy subjects. These nucleotide changes are associated with the development of hypercoagulation syndrome and high risk of renal failure in patients with chronic glomerulonephritis. CONCLUSION. The results of thisinvestigation show that at least part of the patients with chronic glomerulonephritis have genetically determined elevation of thrombogenic potential of blood.